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Abstract
Chronic pulmonary diseases are a major cause of
morbidity and mortality and their impact is expected
to increase in the future. Respiratory viruses are the
most common cause of acute respiratory infections
and it is increasingly recognized that respiratory
viruses are a major cause of acute exacerbations of
chronic pulmonary diseases such as asthma, chronic
obstructive pulmonary disease and cystic fibrosis.
There is now increasing evidence that the host
response to virus infection is dysregulated in these
diseases and a better understanding of the
mechanisms of abnormal immune responses has the
potential to lead to the development of new
therapies for virus-induced exacerbations. The aim of
this article is to review the current knowledge
regarding the role of viruses and immune modulation
in chronic pulmonary diseases and discuss avenues
for future research and therapeutic implications.
Keywords: Asthma, cystic fibrosis, chronic obstructive
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Introduction
Chronic diseases are the leading cause of death worldwide
and the third most common group of chronic diseases are
chronic pulmonary diseases that account for an estimated
four million deaths annually [1]. The most prevalent dis-
eases of the respiratory tract are chronic obstructive pul-
monary disease (COPD), asthma, tuberculosis and lung
cancer, and the most common genetic disease is cystic
fibrosis (CF). COPD is estimated to be the fourth leading
cause of mortality by 2030 [2] and an estimated 300 million
people suffer from asthma. COPD, asthma and CF are all
chronic inflammatory conditions but their etiology and
pathogenesis differ markedly. COPD and asthma are
believed to be caused by exposure to relevant environmen-
tal agents (mainly cigarette smoke and aeroallergens,
respectively) in patients with a susceptible genetic back-
ground, whereas CF is caused by mutations in the CF
transmembrane regulator gene. The typical clinical course
of these conditions is of chronic symptoms that are punc-
tuated by periods of increased symptoms termed ‘acute
exacerbations’. Acute exacerbations are now recognized to
be significant events in the course of the disease and have
enormous implications for patients, their caregivers and for
healthcare providers. Exacerbations accelerate disease pro-
gression, impair quality of life, cause significant morbidity
for patients and are the major cause of mortality. In addi-
tion they are the major drivers of excess healthcare costs as
they often result in unscheduled healthcare visits, treat-
ment costs and above all hospitalizations. Therefore, pre-
venting exacerbations is a major therapeutic goal in all
t h r e ed i s e a s e sa n do n et h a th a sn o tb e e na c h i e v e dw i t h
currently available treatments.
Despite the differences between COPD, asthma and
CF, all three have in common that respiratory virus infec-
tions are a major trigger of acute exacerbations. An
important mechanism underlying this may be impaired
host immune responses to virus infection and a better
understanding of these mechanisms has the potential to
lead to the development of new therapies that may be
beneficial in different chronic pulmonary diseases. The
aim of this article is to review the current knowledge
regarding the role of viruses and host immune responses
in asthma, COPD and CF, and discuss avenues for future
research and therapeutic interventions.
Induction of chronic respiratory diseases by viruses
Although this article primarily focuses on acute exacer-
bations of chronic respiratory diseases, virus infection
has also been implicated in the induction of asthma.
Asthma is strongly related to a genetic predisposition to
develop allergic reactions to aeroallergens. However, not
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it has been proposed that other environmental factors
may act as ‘triggers’ to the development of asthma in
genetically susceptible individuals. One such factor that
has attracted much research interest is respiratory virus
infections, in particular infection with respiratory syncy-
tial virus (RSV). In the majority of cases RSV causes a
self-limiting upper respiratory tract infection, but in
infants under the age of one year it can cause a more ser-
ious infection of the lower respiratory tract - bronchiolitis
- and studies have linked RSV bronchiolitis with an
increased frequency of subsequent wheezing and asthma
[3]. Recently, it has been reported that rhinovirus (RV)
infection is also related to the development of asthma [4].
However, these studies are unable to ascertain the direc-
tion of the relationship between viral infections and
asthma, that is, whether infections cause asthma or infec-
tions occur more frequently in individuals predisposed to
asthma. Recent evidence has emerged supporting the
later hypothesis. A study using data on hospitalization
d u et oR S Vi n f e c t i o nf o ra l lt w i n sb o r ni nD e n m a r k
between 1994 and 2000 found that RSV hospitalization
and asthma were positively associated but that a model
in which asthma ‘causes’ RSV hospitalization fitted the
data significantly better than a model in which RSV hos-
pitalization ‘causes’ asthma [5]. A study of the temporal
relationship between sensitization to aeroallergens and
viral wheeze showed that allergic sensitization led to an
increased risk of wheezing illnesses but viral wheeze did
not lead to increased risk of subsequent allergic sensitiza-
tion [6]. Therefore, the link between asthma and virus
infection may be due to genetically determined altera-
tions in airway or immune responses that predispose
infants both to infection and asthma, rather than virus
infections causing asthma [7]. This will be discussed later
in light of recent developments regarding innate immune
responses in asthma but it is clear that the relationship
between respiratory virus infections and the induction of
asthma is complex and requires further study.
Asthma
Asthma is the most common chronic respiratory disease
affecting up to 10% of adults and 30% of children in the
western world [8]. The Global Initiative for Asthma
(GINA) defines asthma as ‘a chronic inflammatory disor-
der of the airways in which many cells and cellular ele-
ments play a role. The chronic inflammation is associated
with airway hyperresponsiveness that leads to recurrent
episodes of wheezing, breathlessness, chest tightness, and
coughing, particularly at night or in the early morning.
These episodes are usually associated with widespread, but
variable, airflow obstruction within the lung that is often
reversible either spontaneously or with treatment’.T h i s
definition refers to the key physiological marker of asthma
- reversible airflow obstruction, and the key pathological
characteristic - airways inflammation. The characteristic
pattern of inflammation of allergic diseases and also in
asthma involves eosinophils, mast cells and T helper 2
lymphocytes (Th2) and a wide range of inflammatory
mediators. Asthma exacerbations are episodes character-
ized by progressive increase in shortness of breath, cough,
wheezing and chest tightness, or some combination of
these, and increased airflow obstruction that is manifested
by reductions in measurements of lung function such as
peak expiratory flow (PEF). Acute exacerbations are a
c o m m o no c c u r r e n c ei na s t h m aa n dt h es o c i a la n de c o -
nomic burden of asthma exacerbations is substantial, due
to both the direct costs of healthcare utilization and the
indirect costs associated with lost productivity. Current
therapies for asthma consist of bronchodilator and anti-
inflammatory medications, the mainstay of which are
inhaled b2-agonists and inhaled corticosteroids, respec-
tively. These are highly effective in relieving symptoms
and reduce exacerbations by approximately 50% in clinical
trials [9]. However, in ‘real life’ surveys of asthmatics a sig-
nificant proportion of patients continue to experience
acute exacerbations despite therapy and, therefore, preven-
tion/treatment of exacerbations remains a major unmet
clinical need in asthma [10-12].
Viruses and asthma exacerbations
It has long been recognized that viral respiratory tract
infections are triggers for exacerbations of asthma in
both adults and children but early studies reported low
detection rates of viruses in asthma exacerbations casting
doubt on this association. The development of highly
sensitive and specific molecular diagnostic techniques
using polymerase chain reaction (PCR) technology led to
a reappraisal of the role of virus infections in asthma.
Studies using PCR detected viruses in approximately 80%
to 85% of asthma exacerbations in school-aged children
and 60% to 80% of exacerbations in adults. Although
respiratory virus infection can be detected in stable
asthma patients detection rates are consistently lower
than in exacerbated patients [13,14]. Therefore, these stu-
dies suggest that the majority of asthma exacerbations
are associated with respiratory virus infections and that
the low detection rates in earlier studies were a conse-
quence of diagnostic methods with a low sensitivity. The
most common viruses detected in these studies were RV.
RVs are members of the picornaviridae family and are
the most common cause for the common cold in both
children and adults. More than 100 serotypes exist. Virus
typing classified RVs into RV-A and RV-B groups based
on susceptibility to anti-viral drugs and on genetic
sequence similarity. More recently a newly identified
group termed RV-C has been identified based purely on
sequencing data [15]. Other respiratory viruses have been
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influenza, RSV, coronaviruses, human metapneumo-
viruses, parainfluenza viruses (PIV) and adenoviruses.
However, in a recent study in children the only virus type
significantly associated with asthma exacerbations was
RV [16]. The risk of exacerbation following virus infec-
tion is influenced by other factors such as allergy and
environmental pollution. Allergen sensitization, exposure
to sensitizing allergens, and respiratory virus infection act
in a synergistic manner to significantly increase the risk
of hospitalization with acute asthma in both adults [17]
and children [18]. The presence of high ambient levels of
nitric oxide(NO) is also associated with an increased risk
of exacerbation following RV infection [19].
Understanding the mechanisms of virus-induced
exacerbations is important for treatment strategies
Following discovery of the role of RV in asthma exacer-
bations research attention has focused on the mechan-
isms of susceptibility to virus infection in asthmatics. RV
infection in healthy individuals results in a predominantly
upper respiratory symptom syndrome (‘common cold’),
whereas in asthmatics infection results in lower respira-
tory symptoms and airflow obstruction (’acute exacerba-
tion’). A study of co-habiting partners discordant for the
presence of asthma demonstrated that asthmatics do not
have a higher frequency of RV infections but have more
severe lower respiratory symptoms and changes in airway
physiology [20]. Similar results have been reported in
experimental RV infection studies in asthmatics and non-
asthmatic control subjects [21]. Therefore, it would
appear that the consequences of virus infection in asth-
matics are more severe than in non-asthmatics. Under-
standing the mechanisms underlying increased disease
severity is crucial to developing new strategies to treat
virus-induced exacerbations.
Biology of rhinovirus infection
Most research into virus-induced asthma exacerbations
has focused on RV as these are the most common viruses
detected in asthma exacerbations and well-characterized
models of RV infection exist both in vitro and in vivo.
RVs primarily enter and replicate in epithelial cells in the
respiratory tract and trigger a cascade of immune and
inflammatory responses. Following viral entry into a cell,
uncoating of the virus leads to the release of viral RNA
that is recognized by pattern recognition receptors
including toll-like receptors (TLR)-3, -7 and -8, and the
cytosolic RNA helicases, retinoic acid inducible gene I
(RIG-I) and melanoma differentiation-associated protein-
5 (MDA-5) [22,23]. The interactions between ligand and
receptor trigger signaling cascades ultimately resulting in
the activation of transcription factors such as interferon
regulatory factor (IRF)-3 and-7, nuclear factor-B( N F -
B) and activating transcription factor 2 (ATF2). These
activated transcription factors translocate to the nucleus
and induce transcription of the type I interferons (IFN-a
and -b) and pro-inflammatory cytokines including inter-
leukin (IL)-8/CXCL8, IL-6, epithelial-derived neutrophil-
activating peptide 78 (ENA-78/CXCL5) and IFN-g-
induced protein 10 kDa (IP-10/CXCL10)[24-28]. IFN-a
and -b have both a direct antiviral effect through inhibi-
tion of viral replication in cells and an indirect effect
through stimulation of innate and adaptive immune
responses. The direct antiviral activity of type I IFNs is
mediated by various mechanisms including blocking viral
entry into cells, control of viral transcription, cleavage of
RNA and blocking translation. These effects are mediated
through the up-regulation of interferon stimulated genes
(ISGs) and the production of antiviral proteins. The
indirect antiviral effect is mediated through induction of
natural killer cell cytotoxicity [29], up-regulation of the
expression of major histocompatibility complex 1 (MHC-
1) on cells and up-regulation of co-stimulatory molecules
on antigen-presenting cells. Therefore, a robust inter-
feron response is central to effective antiviral responses
and resolution of virus infections. Recently a novel class
of interferons termed type III interferons, or interferon-
lambda (IFN-l) has been described. The type III IFNs
consist of IFN-l1, 2, 3 (respectively, IL-29, IL-28A and
IL-28B) [30]. The IFN-ls utilize a different receptor than
IFN-a/b but appear to have functional similarities, how-
ever much more is known about the mechanism of action
of IFN-a/b.
The pro-inflammatory mediators and cytokines induced
by RV infection lead to chemoattraction of inflammatory
cells such as neutrophils, lymphocytes and eosinophils.
This inflammatory response contributes to virus clearance
but is also responsible for the pathology induced by RV
infections. The balance between antiviral and inflamma-
tory responses following virus infection is likely to deter-
mine the clinical outcome of the infection. An effective
antiviral response rapidly controls viral replication with a
minimal inflammatory response and limited clinical illness.
If antiviral responses are inadequate this is likely to result
in uncontrolled viral replication, greater inflammatory
response and more severe clinical illness (Figure 1). The
evidence that clinical illness following virus infection is
more severe in asthmatics has stimulated research into
possible dysregulation of antiviral and inflammatory
responses in asthmatics.
Inflammatory and immune responses to virus infection in
asthma
In 2005 Wark et al. examined the kinetics of virus repli-
cation in bronchial epithelial cells obtained from asth-
matics and healthy volunteers and reported that viral
replication is increased in cells from asthmatics
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f i r s tr e p o r ti n d i c a t i n gt h a tt h ei n n a t ei m m u n er e s p o n s e
to virus infection may be impaired in asthma. Further-
more, the authors demonstrated that production of IFN-
b was impaired in asthmatics and administration of exo-
genous IFN-b resulted in restoration of a normal anti-
viral response, and this was confirmed in a subsequent
study [32]. Deficient IFN-b production by bronchial
epithelial cells [33], as well as deficient IFN-a produc-
tion by peripheral blood mononuclear cells [34-36] and
dendritic cells [37] has also been reported in asthma.
Our group has also shown that IFN-a and IFN-b pro-
duction by alveolar macrophages is impaired in asth-
matics (manuscript submitted). Furthermore, deficient
IFN-l production by epithelial cells and alveolar macro-
phages in asthmatics has also been reported and related
to clinical outcomes following experimental RV [38].
However, other groups have not reported deficient IFN
induction in epithelial cells from asthmatics [39,40]. In
experimental RV infections virus loads were higher and
virus shedding prolonged in asthmatics but this was not
statistically significant [21,41]. Therefore, although inter-
feron deficiency is an exciting new mechanism underly-
ing increased severity of virus infection in asthma it has
not been conclusively demonstrated to occur in all asth-
matic subjects studied. The studies in question were
small with different experimental conditions such as cell
culture techniques and virus dose. It is also possible that
interferon deficiency occurs in some asthmatics only
and it may also be related to disease severity, disease
control or degree of atopy. Further studies with more
subjects and careful patient selection and characteriza-
tion are required to provide answers to these ongoing
research questions.
Virus infection of 
epithelial cells
NORMALS ASTHMATICS
Robust interferon
responses
Up-regulation of 
interferon-
stimulated genes
Strong NK cell and 
Th1 cell responses
Robust  antiviral responses
Minimal inflammatory response
Minimal inflammation
Short-lived, upper respiratory symptoms only
Virus infection of 
epithelial cells
Impaired interferon
responses
Uncontrolled viral 
replication
Cell necrosis
Excessive inflammatory 
response
↑IFN-γ
Predominant Th2 cells
↓IFN-γ
EXACERBATION
Figure 1 Consequences of virus infection in healthy individuals and asthmatics. Virus infection in non-asthmatics (left-hand panel) induces
robust interferon and Th1 cell responses with rapid control of viral replication and minimal inflammation. In asthmatics (right-hand panel)
impaired interferon and Th1 responses results in uncontrolled viral replication and an exaggerated inflammatory response.
Singanayagam et al. BMC Medicine 2012, 10:27
http://www.biomedcentral.com/1741-7015/10/27
Page 4 of 12If interferon production in response to virus infection is
impaired in asthmatics what are the possible molecular
mechanisms underlying this? The discovery that IFN-a,
IFN-b and IFN-l are all deficient suggests that it is not a
genetic defect as IFN-a and IFN-b are on different genetic
loci than IFN-l. A key family of proteins regulating both
interferon production and allergic inflammation are the
suppressor of cytokine signaling family (SOCS), and one
member of this family, SOCS1, is a potent negative regula-
tor of type I and type II interferons and of Th2 inflamma-
tion [42,43]. SOCS1 is induced by type II cytokines such
as IL-13 [44] and, therefore, persistent Th2 inflammation
may result in chronic up-regulation of SOCS1 and
impaired interferon responses, but this hypothesis requires
further investigation.
Inflammatory responses to virus infection in asthma
In vitro infection of airway epithelial cells with RV
induces the production of inflammatory mediators and
this has also been reported in vivo in both experimental
and naturally-acquired viral infections. Chemokines and
cytokines such as IL-8, IL-6 and regulated on activation,
normal T-cell expressed and secreted (RANTES) have
been detected during virus infections in asthmatic
patients [45-49]. However it remains unclear whether the
inflammatory response following virus infection differs
quantitatively or qualitatively in asthmatics. One experi-
mental RV infection study reported increased nasal
lavage levels of IL-8 and IL-1b in asthmatics [46] but not
in control subjects; however, another study reported no
differences in IL-6, IL-8, IL-11 and granulocyte-mono-
cyte-colony stimulating factor (GM-CSF) levels in either
nasal lavage or sputum between asthmatics and non-
asthmatics [45]. Increased sputum levels of IL-10 but not
RANTES or IL-8 have been reported in asthmatics [48].
These conflicting results highlight the need for further
studies evaluating the inflammatory profile (preferably in
the lower airway) in well-characterized patients and non-
asthmatic controls following virus infection.
Many of the inflammatory mediators produced are che-
moattractants and, therefore, following virus infection
inflammatory cells are recruited to the lungs. A number of
different inflammatory cells have been identified in both
naturally-occurring and experimental virus infections in
asthma. Although stable asthma is characterized by eosi-
nophilic inflammation, a number of studies have identified
neutrophils as the key inflammatory cell in virus-induced
asthma exacerbations [21,50-52]. Neutrophils release
bioactive mediators such as the protease neutrophil elas-
tase that have effects such as stimulation of mucous pro-
duction and, therefore, are likely key contributors to the
pathogenesis of asthma exacerbations. Another key cell
involved in immune and inflammatory responses in the
lungs is the macrophage. There is evidence that RVs can
infect macrophages and that in asthmatics macrophage
responses to virus infection are altered. Our group has
reported that RVs infect macrophages and induce TNF-a
production [53] and that production of the cytokine IL-15,
that plays a key role in linking innate and adaptive anti-
viral immune responses and promoting T cell anti-viral
immune responses, is impaired in asthmatics [53]. As
described previously, macrophage production of IFNs in
response to virus infection is also impaired in asthma [38].
Therefore, there is evidence of impaired antiviral
responses in asthmatics in macrophages as well as respira-
tory epithelial cells.
Increased lymphocyte numbers in bronchoalveolar
lavage (BAL) and bronchial biopsies in experimental RV
infection in asthmatics has been reported, with increases
in CD4+, CD8+ and NK cells [21,54]. Abnormalities of the
acquired immune system in stable asthma have been well
described with skewing of acquired immune responses
t o w a r d saT h 2p r o f i l e .A sr o b u s ta n t i v i r a lr e s p o n s e s
require an adequate Th1 response it is possible that in dis-
eases such as asthma with predominant Th2 cells antiviral
immunity is impaired. Impaired levels of the Th1 cyto-
kines IL-12, -15, -18 and IFN-g have all been reported in
asthma [21,55-57]. In human experimental RV infection
lower respiratory symptoms, bronchial hyperreactivity,
reductions in blood total and CD8+ lymphocytes and
virus load are related to deficient IFN-g,I L - 1 2o rI L - 1 5
responses and to augmented IL-4, IL-5, and IL-13
responses [21,55]. Sputum IFN-g/IL-5 messenger RNA
ratio following virus infection is inversely related to both
peak cold symptoms and the time to viral clearance [58].
Therefore, augmented Th2 and deficient Th1 immune
responses are associated with greater clinical illness fol-
lowing RV in asthma.
Induction of asthma
The identification of impaired innate immunity in asthma
suggests a possible mechanism not only for virus-induced
asthma exacerbations but also for the link between respira-
tory virus infections and the subsequent development of
asthma. It is possible that infants who will develop asthma
in later life have impaired immune responses from birth
and, therefore, are more likely to develop more severe dis-
ease manifestations (for example, bronchiolitis) following
respiratory virus infection. Most studies to date have
focused on the role of the acquired immune system and
identified reduced IFN-g production as a significant risk
factor both for subsequent wheezing illness and allergic
sensitization [59-61]. No studies have investigated innate
immune responses in infants prior to the development of
symptomatic asthma but impaired IFN-a production has
been reported in older children with atopic asthma [35].
In conclusion there is evidence that both innate and
acquired immune responses in asthmatics are impaired
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induced asthma exacerbations and the link between virus
infections and the subsequent development of asthma in
infants. Further studies are needed to determine whether
these deficiencies are common to all asthmatics, whether
they represent a specific asthma phenotype and how they
relate to conventional measures of asthma control.
Another important research question is whether new
interventions targeting the interferon pathways can pre-
vent asthma exacerbations and even potentially prevent
the development of asthma in infants.
Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is the
most common chronic respiratory condition in adults.
The Global Initiative for Obstructive Lung Disease
(GOLD), a collaboration between the World Health
Organization and the National Heart Lung and Blood
Institute, defines COPD as ‘a preventable and treatable
disease with some significant extrapulmonary effects that
may contribute to the severity in individual patients. Its
pulmonary component is characterized by airflow limita-
tion that is not fully reversible. The airflow limitation is
usually progressive and associated with an abnormal
inflammatory response of the lung to noxious inhaled
particles or gases’ [62]. The main etiological agents linked
with COPD are cigarette smoking and biomass exposure
and the inflammatory response consists of neutrophils,
macrophages and CD8+ T cells and, therefore, differs
from the allergic inflammation seen in asthma. Pulmon-
ary inflammation is further amplified by oxidative stress
and excess proteases released by inflammatory cells
recruited to the lung. As in asthma, acute exacerbations
are a common occurrence in COPD and become more
frequent as the disease progresses [63]. Exacerbations are
a major cause of morbidity, mortality and healthcare
costs and accelerate decline in lung function [64] and
quality of life [65] in COPD patients. Historically, bacter-
ial infections have been considered the predominant
infectious etiology, however epidemiological data show-
ing a greater frequency of exacerbations in the winter
months [66] and frequent coryzal symptoms preceding
exacerbations suggest a causal role for viruses [67]. Older
studies using cell culture and serologic diagnostic tests
detected viral infection in only approximately 10% to 20%
of exacerbations [68,69]. However, these diagnostic
methods have low sensitivity for virus detection especially
for RVs that are the most common cause of upper
respiratory tract infections. More recent studies using
modern PCR-based techniques have allowed a re-evalua-
tion of the importance of viruses in COPD exacerbations
and these studies have shown the presence of viruses in
47% to 56% of exacerbations [70-73]. A recent systematic
review evaluated weighted mean prevalence of respiratory
viruses detected by PCR in patients with acute exacerba-
tions of COPD. Eight studies were included with an over-
all prevalence of 34.1%, with picornaviruses including
RVs being the most frequently detected pathogen, fol-
lowed by influenza, parainfluenza, RSV and adenoviruses
[74]. Although these studies have higher detection rates
they are likely to have underestimated the role of viral
infections in COPD exacerbation as they evaluated
patients at the time of presentation to healthcare services
which often occurs considerably later than the onset of
exacerbation and by which time virus may no longer be
detectable.
Experimental infection studies in COPD
Although viruses are frequently detected in COPD
exacerbations, their presence during exacerbations does
not prove a definite causative role. Experimental infection
using RV provides a novel tool for investigating relation-
ships between virus infection and exacerbations. Such
studies have been previously conducted in asthma and
yielded important insights into the mechanisms linking
virus infection to exacerbations in asthma. A recent
study from our group reported the first experimental RV
infection study in COPD [75]. COPD patients and non-
obstructed controls were infected with RV with sequen-
tial measurement of symptoms, lung function, inflamma-
tory markers and virus load. Following RV infection,
COPD subjects developed symptomatic colds followed by
the typical lower respiratory symptoms of an acute
exacerbation. Symptoms were accompanied by objective
evidence of airflow limitation and airways inflammation
and inflammatory markers correlated with virus load.
Virus was detected in airway samples prior to the onset
of symptoms and viral clearance was followed by symp-
tom resolution and return of inflammatory markers to
baseline levels. Therefore, this study directly links
respiratory virus infection to lower respiratory symptoms,
airflow obstruction and airways inflammation in COPD
and provides novel evidence supporting a causative role
for RV infection in COPD exacerbations.
Mechanisms of virus-induced COPD exacerbations
Much less is known regarding mechanisms of virus-
induced exacerbations in COPD compared to asthma. In
the experimental infection study, symptoms, airflow
obstruction and airways inflammation were more severe
in the COPD subjects compared to non-obstructed con-
t r o l s[ 7 5 ] .T h e r e f o r e ,a si st h ec a s ei na s t h m ai tw o u l d
appear that clinical illness following RV infection is more
severe in COPD subjects, but the mechanisms underlying
this are poorly understood. COPD exacerbations are
associated with increased levels of inflammatory media-
tors including tumor necrosis factor-alpha (TNF-a) [76],
IL-8 [76,77], IL-6 [78], and leukotriene B4 [79] and
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nophils [70]. However, few studies have examined the
inflammatory response specific to virus-induced exacer-
bations. Virus infection has been associated with high
levels of IL-6 [80,81] and IP-10 [82,83] and Papi et al.
reported that elevated sputum eosinophils were only seen
in exacerbations in which a virus was present [70].
Others have reported that the presence of RV is not asso-
ciated with significant airway inflammation [84] and that
only exacerbations associated with purulent sputum (pre-
sumed bacterial infection) are associated with airways
inflammation [79]. From the data available no clear con-
clusions can be drawn regarding the inflammatory
response to virus infection in COPD and there are no
studies comparing the effects of naturally-occurring virus
infections in COPD patients and non-COPD controls.
There is evidence from animal models that the inflam-
matory response to virus infection may be exaggerated in
COPD. In a mouse model of COPD utilizing intranasal
administration of lipopolysaccharide and elastase, infec-
tion with RV resulted in increased levels of TNF-a and
IL-13 compared to control mice [85]. This was accompa-
nied by increased airway hyper-responsiveness and
increased mucus production. Similarly, in the human
COPD RV challenge study, increased levels of IL-8 and
neutrophil elastase were reported in COPD subjects
when compared to non-obstructed controls [75]. These
studies suggest that COPD is associated with an exagger-
ated inflammatory response to viral infection and this
may explain the increased severity and duration of symp-
toms seen in these patients.
In vitro studies have shown that cigarette smoke impairs
release of IFN-b and IFN-a [86]. BAL cells from COPD
patients infected ex vivo with RV demonstrated deficient
induction of IFN-b with similar trends for deficient induc-
tion of IFNs-a and -l, associated with deficiency of the
interferon stimulated gene CXCL10 [75]. Similar findings
have been reported in a mouse model where persistence
of RV, increased airways inflammation and deficient
induction of IFNs-a,- b and -g were reported in COPD
mice compared to controls [85]. However in vitro RV
infection of epithelial cells from COPD patients resulted in
higher virus load and increased inflammatory mediators,
but no differences in interferon production compared to
cells from control subjects [87]. Further studies examining
the role of interferon deficiency in viral exacerbations are
required as this may lead to potential future therapeutic
application of interferon therapy in reducing exacerbation
severity in COPD. RVs bind to cells via intercellular adhe-
sion molecule-1 (ICAM-1, major group RVs) or members
of the low-density lipoprotein receptor family (minor
group RVs). ICAM-1 is upregulated on the bronchial
epithelium of patients with COPD [87,88] and, therefore,
it is possible that increased ICAM-1 levels may permit
greater virus binding and increased viral entry into epithe-
lial cells in COPD patients.
Virus infection and stable COPD
The majority of studies have detected viruses at a greater
frequency during acute exacerbations compared to the
stable state. One study indicated that RSV is detected in
nasal lavage at a similar frequency of around 25% in the
stable state and during exacerbations [67]. This was fol-
lowed by a similar study reporting detection of RSV in
about 30% of sputum samples, with detection being
related to greater airway inflammation and to a faster
decline in lung function [89]. However, other studies have
not reported increased RSV detection in stable COPD
[70,71]. A study comparing virus loads between infants
with acute respiratory infections and adult COPD patients
found that virus loads were 2000-fold higher in the infants,
suggesting low-grade virus infection in COPD [90]. The
disparity between these findings is likely to be due to a
combination of factors including differing sensitivity of the
PCR techniques used, differences in severity of COPD
patients included or differences in the populations studied
[91].
Latent infection by adenovirus has also been proposed to
be involved in the pathogenesis of COPD. Lung tissue
from COPD patients has been demonstrated to carry
more group C adenoviral DNA than matched non-
obstructed smokers [92]. Latent adenoviral infection in
combination with cigarette smoke exposure in a guinea
pig model caused an increase in lung volumes, airspace
volume and reduced surface to volume ratio compared to
s m o k ee x p o s u r ea l o n e[ 9 3 ] .A dditionally, adenovirus
detection has been shown to be similar in exacerbated and
stable COPD patients [94]. Some authors have postulated
that the presence of RSV and adenovirus in stable COPD
may contribute to the pathogenesis of the disease as there
are some common pathologic features between respiratory
viral infection and COPD including a predominance of
CD8+ T lymphocytes. However, this remains a largely
unproven hypothesis.
Cystic Fibrosis
Cystic fibrosis (CF) is an autosomal recessive disease
caused by mutations in the gene for the cystic fibrosis
transmembrane regulator (CFTR) protein. Defective
CFTR function leads to abnormal transport of chloride
and sodium across the pulmonary epithelium, resulting
in viscous secretions in the lungs, recurrent bacterial
infections and progressive loss of lung function. Pulmon-
ary involvement is the most common manifestation of
t h ed i s e a s ea n dr e s p i r a t o r yf a i l u r et h em o s tc o m m o n
cause of death. Respiratory infections are the leading
cause of morbidity, decline in lung function and hospita-
lizations due to acute exacerbations. The major cause of
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ered to be bacterial infection, with Pseudomonas aerugi-
nosa the most common organism detected. There has
been relatively little research on the role of virus infec-
tions in CF but recent studies have suggested that viruses
have a significant impact on the CF patient.
Viruses and CF exacerbations
The role of respiratory viruses in CF exacerbations is likely
to have been under-appreciated in the past because older
studies investigated only one virus type and the detection
methods used were not sufficiently sensitive. Newer PCR
techniques have helped to improve detection and it is now
becoming clear that viruses are implicated in exacerba-
tions in CF. Previous studies using serology, culture and
immunoflourescence detected viruses in 10% to 28% of
exacerbations in CF patients [95-98]. In contrast, studies
using PCR for virus detection have reported detection
rates of 50% to 60% [99-101]. A number of different
viruses have been detected in CF patients with the most
common being RVs, influenza and RSV. The incidence of
viral infections in children with CF is not elevated in com-
parison to healthy children but the severity of clinical ill-
ness associated with infection is greater [102]. Viral
infections are associated with deterioration in lung func-
tion and more severe clinical illness indicating that they
contribute to disease progression thus demonstrating the
clinical importance of research within this field [100,103].
Mechanisms of virus infection in CF
The mechanisms of viral-induced CF exacerbations and
increased clinical illness are poorly understood with con-
flicting results from published studies. Some authors have
reported increased production of pro-inflammatory cyto-
kines and chemokines by epithelial cells obtained from CF
patients compared to healthy controls [102,104]. However,
others have failed to detect any differences in cytokine
production between CF and normal cells [105,106]. These
differences may be due to different viruses used (RV, RSV,
PIV) and differences in cell culture techniques, but it
remains unclear whether the CF epithelium is intrinsically
pro-inflammatory in response to virus infection. Another
mechanism that has been postulated is a deficiency in
antiviral innate immune responses in CF cells. Increased
replication following PIV infection of CF cells has been
reported and this was corrected by administration of IFN-
a [102]. IFN responses were not impaired but induction of
nitric oxide synthase 2 (NOS2) was impaired in CF. NOS2
is required for production of NO that has potent antiviral
effects and, therefore, impaired NO synthesis may be one
mechanism of impaired antiviral host responses in CF.
Our group has reported reduced IFN-b and IFN-l pro-
duction and reduced ISGs in CF epithelial cells [107] and,
therefore, IFN deficiency may be relevant to CF as well as
in asthma and COPD. Holtzman has proposed that ‘hyper-
susceptibility’ to virus infection, via defective interferon
pathways, is a unifying pathway in asthma, COPD and
now CF [108].
Bacteria-virus interactions in pulmonary disease
Both bacterial and virus infections are common in CF
a n dC O P Da n d ,t h e r e f o r e ,c o - i n f e c t i o n sa r el i k e l yt ob e
common. There is now increasing evidence that both
viral and bacterial infections can modulate host immune
responses and increase susceptibility to subsequent infec-
tion. There is abundant evidence from both human stu-
dies and animal models that influenza infection impairs
antibacterial immunity and this can result in secondary
bacterial pneumonia [109,110]. However, much less is
known regarding the effect of other respiratory viruses,
such as RVs, on susceptibility to bacterial infection.
In vitro studies have reported that RV infection increases
bacterial adhesion to epithelial cells [111-113] and
impairs macrophage immune responses to bacterial pro-
ducts [114]. We have found that experimental RV infec-
tion in COPD is followed by secondary bacterial infection
in 60% of patients and this is related to deficiency of the
antimicrobial peptides elafin and secretory leukoprotease
inhibitor (SLPI) (submitted manuscript). There are also
studies indicating that virus-bacteria interactions influ-
ence host immune responses in CF. Chattoraj et al.
reported that RV infection of CF cells liberates plank-
tonic bacteria from biofilm [115]. Planktonic bacteria
express virulence factors and stimulate inflammatory
responses more readily compared to biofilm bacteria and
this was manifested by increased cytokine responses. Evi-
dence is also emerging that bacterial infection can
increase susceptibility to viral infection. Infection of
epithelial cells by Haemophilus influenzae (a common
organism in COPD) increases susceptibility to infection
by RV, possibly by up-regulation of ICAM-1 [116]. CF
cells infected with mucoid P.aeruginosa and then with
RV produced less IFN and viral loads were higher com-
pared to cells infected with the RV alone [117]. This
effect was not seen in normal epithelial cells infected
with Pseudomonas a n dw a sr e l a t e dt ot h ei n h i b i t i o no f
Akt phosphorylation and IRF-3 activation - both pre-
requisites for the IFN response to RV infection.
It is widely acknowledged that the main infectious
cause of asthma exacerbations is virus infection and it is
believed that bacteria play only a minor role. However, a
recent study using culture-independent molecular meth-
ods for bacterial detection reported that the bacterial
flora in the airways of asthmatics is closer to that of
COPD patients than of non-asthmatics [118]. The role of
bacteria in asthma exacerbations needs to be revisited as
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genesis of asthma exacerbations. This is a fertile area for
further research.
Our knowledge of the interactions between respiratory
viruses and bacteria, and how these influence host
immune responses in pulmonary diseases, is still at an
early stage. Further research is required to understand
better these complex relationships and to explore the
implications they may have for the development of new
therapies.
Conclusions
There is now convincing data implicating respiratory
viruses as a major cause of acute exacerbations in asthma,
COPD and CF. In all these conditions there is evidence
that host immune responses to virus infection are
impaired, but whether this occurs through a common
mechanism, or whether mechanisms differ between the
different diseases is unclear. Further research is needed to
elucidate the exact mechanisms of increased susceptibility
to virus infection in pulmonary diseases, the interactions
between viruses and bacteria and how these impact on
host immune responses. A better understanding of these
mechanisms has the potential to lead to the development
of novel therapies that will reduce the impact of acute
exacerbations in chronic pulmonary diseases.
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